NEW YORK , April 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its Board of Directors has appointed
11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA) NEW YORK , April 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and
NEW YORK , April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its upsized underwritten
NEW YORK , April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public
NEW YORK , March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the
Late-breaking presentation will feature the first clinical data from a biopsy-based substudy supporting obeticholic acid’s ability to reverse or stabilize fibrosis and cirrhosis in primary biliary cholangitis (PBC) patients NEW YORK , March 23, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals,
NEW YORK , March 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
Worldwide Net Ocaliva ® (obeticholic acid or OCA) full year 2017 net sales of $129.2 million , fourth quarter 2017 sales of $37.3 million U.S. Prescribing Information for Ocaliva ® updated to reinforce appropriate dosing in PBC patients with advanced cirrhosis Continuing to advance industry
Results from REVERSE are intended to serve as the basis for seeking marketing approval of OCA for the treatment of NASH patients with compensated cirrhosis REGENERATE and REVERSE pivotal trials expand Intercept’s leadership’s position in NASH NEW YORK , Feb.
NEW YORK , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and
